

BMB Reports – Manuscript Submission

Manuscript Draft

Manuscript Number: BMB-15-173

Title: Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice

Article Type: Article

Keywords: Anti-inflammatory; Bile acid; Lipogenesis; Peroxisome proliferator-activated receptor- γ ; Ursodeoxycholic acid

Corresponding Author: Ji-Young Cha

Authors: Ah-Reum Oh^{1,#}, Jin-Sik Bae^{1,#}, Junghoon Lee¹, Eunji Shin¹, Byeong-Chul Oh¹, Sang-Chul Park¹, Ji-Young Cha^{1,2,*}

Institution: ¹Department of Molecular Medicine, Lee Gil Ya Cancer and Diabetes Institute, Gachon University,

²Gachon Medical Research Institute, Gil Hospital,

Manuscript Type: Article

Title: Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice

Author's name: Ah-Reum Oh^{1,#}, Jin-Sik Bae^{1,#}, Junghoon Lee¹, Eunji Shin¹, Byeong-Chul Oh¹, Sang-Chul Park¹, and Ji-Young Cha^{1,2,*}.

Affiliation: ¹Department of Molecular Medicine, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 406-840, ²Gachon Medical Research Institute, Gil Hospital, Incheon 406-840, Korea

Running Title: UDCA effects on age-related lipid homeostasis

Keywords: Anti-inflammatory; Bile acid; Lipogenesis; Peroxisome proliferator-activated receptor- γ ; Ursodeoxycholic acid.

Corresponding Author's Information:

Ji-Young Cha, Ph.D.
Department of Molecular Medicine
Lee Gil Ya Cancer and Diabetes Institute
Gachon University
155 Gaetbeol-ro, Yeonsu-gu, Incheon 406-840, Korea
Tel. No. +82 32 899 6070, Fax No. +82 32 899 6032
E-mail address. jycha1014@gachon.ac.kr

ABSTRACT

Ursodeoxycholic acid (UDCA), a natural, hydrophilic nontoxic bile acid, is clinically effective for treating cholestatic and chronic liver diseases. We investigated the chronic influence of UDCA on age-related lipid homeostasis and underlying molecular mechanisms. **Twenty-week-old** C57BL/6 male and female mice were fed a diet with or without 0.3% UDCA supplementation for 25 weeks. UDCA significantly reduced weight gain, adiposity, hepatic triglyceride, and hepatic cholesterol without incidental hepatic injury. UDCA-mediated hepatic triglyceride reduction was associated with downregulated hepatic expression of peroxisome proliferator-activated receptor- γ , and of other genes involved in lipogenesis (*Chrebp*, *Acaca*, *Fasn*, *Scd1*, and *Me1*) and fatty acid uptake (*Ldlr*, *Cd36*). The inflammatory cytokines *Tnfa*, *Ccl2*, and *Il6* were significantly decreased in liver and/or white adipose tissues of UDCA-fed mice. These data suggest that UDCA exerts beneficial effects on age-related metabolic disorders by lowering hepatic lipid accumulation, while concurrently reducing hepatocyte and adipocyte susceptibility to inflammatory stimuli.

INTRODUCTION

Bile acids are cholesterol-derived bioactive amphipathic molecules that play essential roles in many processes required for the maintenance of a healthy lifespan (1). In addition to their classical role as endogenous detergents that regulate bile flow and facilitate intestinal absorption of lipids, nutrients, and lipid-soluble vitamins (2), bile acids are also metabolically active signaling molecules that modulate their own levels, and also regulate triglyceride, cholesterol, glucose, and energy metabolism. Bile acid composition changes as mice age, and several bile acids are increased in the serum of long-lived mouse strains that exhibit attenuated pro-aging pathway signaling (3, 4).

Ursodeoxycholic acid (UDCA) is a natural, hydrophilic bile acid that is used to treat various hepatic and digestive diseases, including cholestasis and primary biliary cirrhosis.(5, 6) Oral UDCA administration increases UDCA levels in serum and bile by competitively inhibiting ileal absorption of natural, toxic endogenous bile salts (7, 8). The main mode of action of UDCA is likely via displacement of endogenous hepatotoxic bile salts to increase the contribution of non-toxic hydrophilic bile acids in the total bile acid pool. In liver disease, UDCA provides clinical benefit by mediating hepatocyte cytoprotection, choleresis, and immunomodulatory functions. The cytoprotective effect of UDCA partly results from inhibition of cell apoptosis (9). UDCA also reduces mitochondrial membrane permeability and the release of hydrolytic enzymes from damaged hepatocytes, and improves cell resistance to reactive oxygen species (10, 11). Recently, UDCA was reported to improve hepatic steatosis and insulin sensitivity by inducing the excretion of hepatic lipids, inhibiting hepatic long-chain free fatty acid uptake, and suppressing the miR-34a/SIRT1/p53 pathway in obese mice (12-14). All these effects support the hypothesis that UDCA could be a useful molecule for preventing age-related obesity, steatosis, and inflammation.

We investigated the influence of UDCA on age-related accumulation of body fat, and the molecular mechanisms involved in the anti-obesity effects of UDCA in the liver and white adipose tissue. The results of the present study provide a basis for considering UDCA administration as a therapeutic strategy for treating age-related obesity.

RESULTS

UDCA decreases weight gain and fat accumulation

To determine whether UDCA affects age-related body fat accumulation, adult male and female mice were fed a diet with or without 0.3% UDCA for 25 weeks, with body weight monitored weekly (Fig. 1A). Body weight gain was similar in Control and UDCA-fed mice until 8 weeks, and then tended to decrease in UDCA mice thereafter. The difference in body weight between Control and UDCA-fed mice was significant after 15 weeks in females ($p < 0.05$). Although UDCA also slowed weight gain in male mice after 13 weeks, this difference did not achieve statistical significance ($p = 0.06-0.07$). The decreased body weight in female mice by UDCA was mainly due to decreased total body fat ($\downarrow 17\%$) and not lean body mass ($\uparrow 9\%$) (Fig. 1B). To rule out reduced food intake causing declining body weight gain, we monitored food and water intake in metabolism cages. Food intake was not decreased in UDCA-fed mice, and even slightly increased in male UDCA-fed mice (Fig. 1C). Water intake also showed a similar trend of increased drinking by UDCA mice vs Controls (Fig. 1C). Next, we removed and weighed livers and white adipose tissue (gonadal fat). Liver and gonadal adipose weights were decreased by UDCA treatment in both genders, but to differing extents. Male mice showed significantly reduced liver mass ($\downarrow 26\%$) by UDCA, whereas female mice showed significantly decreased white adipose tissue mass ($\downarrow 20\%$) by UDCA. These results indicated that UDCA ameliorates age-related body weight gain and adiposity.

UDCA changes plasma or liver parameters and is not hepatotoxic

To characterize the impact of UDCA on metabolic parameters, we examined liver and plasma TG and cholesterol levels (Fig. 2). Plasma TG and total cholesterol levels were both significantly 1.9-fold higher in male vs female Control mice (Fig. 2A). However, neither parameter was altered by UDCA treatment, except for the increased plasma TG in male UDCA vs Control mice.

Liver TG levels were also significantly 1.9-fold higher in male vs female Control mice (Fig. 2B). UDCA feeding significantly decreased liver TG by $\approx 31\%$ and $\approx 61\%$ in male and female mice, respectively, resulting in similar final absolute levels. UDCA also decreased hepatic total cholesterol levels by $\approx 30\%$ in female mice, although no decreased hepatic cholesterol levels were observed in male mice (Fig. 2B). In accordance with these results, H&E staining revealed decreased lipid droplets in liver sections from UDCA vs Control mice of both genders (Fig. 2C). We examined plasma ALT and AST levels as indicators of liver-injury status (Fig. 2A). Neither ALT nor AST levels were significantly changed by UDCA, in either gender in mice. Taken together, these results indicate that chronic UDCA administration significantly lowers liver lipid accumulation and is not hepatotoxic.

UDCA affects transcription of hepatic genes associated with lipid homeostasis

To understand the molecular mechanisms underlying the lipid phenotypes observed in UDCA-fed mice, we analyzed mRNA expression levels of several genes associated with lipid homeostasis in the liver (Fig. 3). Hepatic lipid homeostasis is tightly regulated by balanced lipid synthesis (lipogenesis), catabolism (fatty acid oxidation), and secretion. The transcription factors responsible for lipid synthesis include PPARG, sterol regulatory element binding protein 1c (SREBP-1c), and carbohydrate response element binding protein

(ChREBP). UDCA significantly reduced *Pparg* mRNA expression in both male and female mouse livers (Fig. 3A). This was reflected at the protein level, whereby UDCA significantly reduced liver expression of PPARG-1, but not -2, in both male and female mice (Fig. 3B). UDCA showed gender-specific effects on two transcription factors, *Srebp-1c* and *Chrebp*, which are responsible for insulin- and glucose-induced lipogenic gene expression, respectively (15). UDCA tended to repress *Srebp1c* mRNA expression in male mice, and significantly reduced expression of the ChREBP isoforms *Chrebp-a* and *Chrebp-b* in female mice (Fig. 3A). Expression of primary lipogenic enzyme targets of these transcription factors, including acetyl-CoA carboxylase alpha (*Acaca*), fatty acid synthase (*Fasn*), malic enzyme 1, NADP(+)-dependent, cytosolic (*Me1*), and stearoyl-Coenzyme A desaturase 1 (*Scd1*), was significantly decreased by UDCA-feeding in female, but not male, mice (Fig. 3A). The mRNA expression of genes involved in fatty acid oxidation, including PPAR alpha (*Ppara*) and PPAR beta/delta (*Pparb/d*), and their target genes such as carnitine palmitoyltransferase 1a (*Cpt1a*), *Cpt1b*, and *Cpt2*, were not significantly altered by UDCA in mice of either gender (not shown). Next, we determined the expression of genes involved in lipid secretion and uptake. Gene expression of the microsomal triglyceride transfer protein (*Mttp*), a key regulator in the assembly and secretion of chylomicrons and very low-density lipoprotein in the intestine and liver, was increased in the livers of UDCA-fed male mice, but not in the livers of female mice (Fig. 3A). This result correlated with increased plasma TG levels observed in UDCA-fed male, but not female mouse livers (Fig. 2A). The mRNA levels of the free fatty acid uptake transporter CD36 molecule (*Cd36*), known to be associated with hepatic steatosis, and low-density lipoprotein receptor (*Ldlr*), were decreased in the livers of UDCA-fed female, but not male, mice (Fig. 3A).

UDCA downregulates inflammatory gene expression in liver and adipose tissues

We tested whether UDCA positively influences age-related inflammatory status, because bile acids reportedly have profound anti-inflammatory properties against liver injury induced by a high-fat diet (16). We examined inflammatory and anti-inflammatory cytokine expression in liver and adipose tissues. Hepatic expression of the key inflammatory cytokine, tumor necrosis factor-alpha (*Tnfa*) was significantly decreased in male mice by UDCA (Fig. 4A). Although not statistically significant, UDCA decreased *Tnfa* mRNA levels in female mouse livers to $\approx 48\%$ of Control values. Chemokine (C-C motif) ligand 2 (*Ccl2*) was significantly decreased in both genders by UDCA. However, anti-inflammatory cytokine *Cd163* expression was significantly increased by UDCA in female, but not male, mouse livers.

In adipose tissue, UDCA administration tended to decrease mRNA levels of *Tnfa* and *Ccl2* in both genders. *Cd163* expression was significantly increased by UDCA administration in the adipose tissues of female, but not male, mice (Fig. 4B). Inflammatory cytokines, such as interleukin-1-beta (*Il1b*) and interleukin 6 (*Il6*) were not changed by UDCA in female mouse adipose tissues. In male mouse adipose tissues, however, *Il1b* tended to decrease, and *Il6* was significantly decreased by UDCA. Adiponectin is an adipokine with a well-established anti-atherogenic, anti-inflammatory, and insulin-sensitizing properties (17). Adiponectin (*Adipoq*) gene expression was increased in UDCA-fed male, but not female, mouse adipose tissue (Fig. 4B). Leptin (*Lep*) mRNA tended to be decreased by UDCA in adipose tissue of both genders, although this change did not achieve statistical significance.

DISCUSSION

UDCA is effective in treating cholestasis and chronic liver diseases. High-dose UDCA effectively improves ALT, serum fibrosis markers, and other relevant metabolic parameters (18, 19). Animal models of nonalcoholic fatty liver disease have shown that UDCA ameliorates insulin sensitivity, and liver steatosis and inflammation (16, 20). Most previous

studies on the potential beneficial effects of UDCA on glucose and lipid metabolism were performed in metabolic disease models of obesity and fatty liver (12, 21, 22). Therefore, we evaluated the chronic effects of UDCA on normal physiology in both male and female mice.

We fed UDCA to adult (20-week-old) mice until 45 weeks of age (old adult), to model human adults who self-administer oral UDCA as a health supplement. The present study demonstrates that chronic UDCA administration protects against age-related weight gain, adiposity, and inflammation. Protection against hepatic fat accumulation in UDCA-fed mice was associated with significant downregulation of genes involved in hepatic lipid synthesis (PPARG, *Chrebp-a/-b*, *Acaca*, *Fasn*, *Me1*, and *Scd1*) and lipid uptake (*Cd36* and *Ldlr*). Moreover chronic UDCA administration decreased inflammatory cytokines such as *Tnfa* and *Ccl2*, while increasing anti-inflammatory cytokine *Cd163* expression in the liver and white adipose tissue. Interesting findings from the present study show gender-specific regulation of lipogenesis and inflammation by UDCA in old-adult mice.

As previously shown (23), plasma TG and cholesterol levels were higher in male vs female mice. Although a UDCA-phospholipid conjugate reportedly reduces elevated serum TG and cholesterol in the nonalcoholic fatty liver and steatohepatitis disease models, unmodified UDCA had no effect on serum TG and cholesterol (16). In accordance with those results, we failed to detect an inhibitory effect of UDCA on plasma TG and cholesterol in both genders; rather, male mice conversely showed slightly increased plasma TG levels after UDCA administration. Therefore, different UDCA formulations should be evaluated for better therapeutic efficacy in improving plasma lipid profiles.

UDCA significantly reduced hepatic TG and cholesterol content in a gender-dependent manner. Hepatic TG levels were decreased by UDCA in both genders, but hepatic cholesterol levels were only decreased in female mice. Of note, the basal hepatic TG levels were higher in male vs female mice, whereas basal hepatic cholesterol levels were higher in females.

Interestingly, plasma insulin and glucose levels were decreased by UDCA, suggesting improved insulin sensitivity (data not shown). An inverse relationship between hepatic TG and insulin sensitivity has been reported (24), therefore, it is reasonable to suggest that UDCA improved hepatic insulin resistance by decreasing levels of hepatic lipids. However, further experiments to specifically define UDCA effects on age-related insulin resistance are needed.

Consistent with decreased hepatic TG and cholesterol, a major effect of UDCA on lipid metabolism was the decreasing hepatic lipid synthesis and lipid uptake in a gender-specific manner. In female, but not male, mice, decreased hepatic TG was associated with reduced expression of important lipogenesis genes, such as *Chrebp*, *Acaca*, *Fasn*, and *Scd1*. In male mice, lipogenesis-related gene expression was unchanged, but genes involved in hepatic lipid uptake and secretion were changed by UDCA. Therefore, the effects of UDCA on lipid metabolism are gender-dependent, and associated with reduced hepatic TG. The effects of UDCA on fatty acid oxidation remain controversial; fatty acid oxidation was increased by UDCA in obese Zucker rats, but unchanged in lean rats and high-fat diet-fed mice (20, 25). In our study, the expression of genes involved in fatty acid oxidation was not changed by UDCA (data not shown). Therefore, we speculate that UDCA decreases hepatic TG by inhibiting two pathways: ChREBP-mediated lipogenesis and PPARG-mediated lipid uptake/secretion.

Chronic inflammation is a pathological characteristic of aging, and increased inflammatory cytokines, such as IL-6, IL-1 β , and TNF α , are linked to many age-related disorders (26). Chronic inflammation is also associated with insulin resistance (27). Production of inflammatory cytokines is stimulated by activated NF κ B and JNK pathways. Phosphorylated NF κ B and I κ B α levels were not changed in livers of mice of either gender by UDCA, but hepatic phospho-JNK was decreased in UDCA-fed mice of both genders (data not shown).

This observation suggests that chronic UDCA administration suppresses age-related inflammatory responses.

In summary, this study provides evidence that chronic UDCA administration can improve age-related obesity and insulin resistance. The underlying molecular mechanisms for these effects may include reduced hepatic lipogenesis and decreased inflammatory responses. These findings support the beneficial effects of UDCA in preventing and treating age-related chronic metabolic diseases, such as insulin resistance and type-2 diabetes.

MATERIALS AND METHODS

Animals

Animal studies were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the Lee Gil Ya Cancer and Diabetes Institute, Gachon University. C57BL/6 12-week-old male and female mice were purchased from Orientbio (Gyeonggi Province, Korea). Mice were maintained on a normal diet (PicoLab[®] Rodent Diet 20, Orientbio) under a 12-h light/dark cycle until age 20 weeks, and then were fed a control formulation (D12450B; Research Diets, Inc., New Brunswick, NJ), either alone or supplemented with 0.3% (w/w) UDCA (Sigma-Aldrich, St. Louis, MO) for 25 weeks, until sacrifice. Body composition was assessed by ¹H-magnetic resonance spectroscopy (BioSpin, Bruker, Billerica, MA). After control or UDCA feeding for 21 weeks, mice were housed singly in metabolic cages for a 4-day period, and food and water intake was measured during the last 2-day period. At the 25-week experimental endpoint, mice were euthanized at the beginning of the light cycle and weighed. Blood samples were collected via the hepatic portal vein, and plasma was obtained by centrifugation at 300 × g for 15 min at 4°C. Livers and gonadal fats were removed, weighed, and either snap-frozen in liquid nitrogen or formalin-

fixed. Liver and plasma samples were stored at -80°C until RNA isolation or biochemical analysis.

Biochemical analysis

Plasma ALT, AST, TG, and total cholesterol levels were determined by automated analysis (Model AU-480; Olympus, Tokyo, Japan). Liver TG and cholesterol profiles were determined using a Cleantech TG-S kit (Asan Pharmacy, Inc., Seoul, Korea) and Cholesterol/Cholesteryl Ester Quantitation Kit (BioVision, Inc., Milpitas, CA), respectively.

Histological staining

Freshly-isolated liver and gonadal fat samples were fixed in neutral-buffered formalin and embedded in paraffin blocks; sections were stained with hematoxylin and eosin (H&E).

RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was isolated from mouse liver and gonadal fat using RNAiso Plus (Takara, Shiga, Japan). Purified total RNA was treated with RNase-free DNase (Roche, Penzberg, Germany), and reverse-transcribed using a QuantiTect[®] Reverse Transcription Kit (Qiagen, Hilden, Germany). Gene-specific primers (Supplementary Table S1) were designed using Primer Express Software (PerkinElmer Life Sciences, Waltham, MA), and validated by analysis of template titration and dissociation curves. Quantitative gene expression analyses were performed on a 7900HT Fast Real-Time PCR System (Life Technologies, Carlsbad, CA) using SYBR[®] Premix Ex Taq[™] II, ROX Plus (Takara). Expression levels were calculated by the $2^{-\Delta\Delta\text{CT}}$ method, using ribosomal protein, large, P0 (*Rplp0*) as the invariant control.

Immunoblot analysis

Total protein was isolated from mouse liver using PRO-PREP Protein Extraction Solution (Intron Biotechnology, Daejeon, Korea) supplemented with phosphatase inhibitors. Immunoblot analysis used the following antibodies: Anti-peroxisome proliferator-activated receptor gamma (PPARG) was from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was from Millipore Inc., (Billerica, MA).

Statistical analysis

Data are expressed as the means \pm standard error of the mean (SEM). Statistical analysis was performed using SPSS (v.17.0; SPSS/IBM Inc., Chicago, IL). **When we compared treatment group to control, we used the Mann-Whitney U test. In that case, we used * or ** to show statistically difference (*, $p < 0.05$; **, $p < 0.01$). However, when we compared two factors, gender and drug, we used the Kruskal-Wallis test. If a significant interaction was evident, group comparisons with the Mann-Whitney U test were performed. Different letters denote groups that are significantly different ($P < 0.05$).**

ACKNOWLEDGEMENTS

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2012R1A1A3018738), and by Gachon University (GCU-2012-5167), both awarded to J-Y Cha.

FIGURE LEGENDS**Figure. 1. Ursodeoxycholic acid decreases age-related weight gain and fat accumulation.**

Male and female mice were fed diets with or without 0.3% UDCA for 25 weeks beginning at 20-week-old. (A) Body weight was monitored weekly. (B) At the end of the experiment, lean mass and fat mass were measured. * $p < 0.05$ vs Controls; ** $p < 0.01$ vs Controls. (C) After Control or UDCA feeding for 21 weeks, food and water intake were measured in metabolic cages. (D) At the end of the experiment, body, liver, and gonadal fat weights were measured. $n = 3$ mice/group for males, and 6 mice/group for females. Results are expressed as the mean \pm SEM. Statistical testing was performed by two-way analysis of variance using gender and drug as factors. A significant interaction was observed between gender and drug, demonstrating that the difference of gender results in altered response to UDCA. Bars with different letters are significantly different, $p < 0.05$.

Figure. 2. Ursodeoxycholic acid changes plasma and liver parameters and is not

hepatotoxic. (A) Plasma ALT, AST, and lipid profiles (B) Liver triglyceride (TG) and cholesterol. Results are expressed as the mean \pm SEM. Statistical testing was performed by two-way analysis of variance using gender and drug as factors. No significant differences among groups were observed for ALT and AST. A statistical difference due to gender (but not drug) was evident for total cholesterol and LDL cholesterol. For the remaining parameters, a significant interaction was observed between gender and drug, demonstrating that the difference of gender results in altered response to UDCA. Bars with different letters are significantly different, $p < 0.05$. (C) Hematoxylin and eosin staining of liver sections show reduced hepatic adiposity after UDCA treatment in both male and female mice. $n = 3$ mice/group for males, and 6 mice/group for females.

Figure 3. Ursodeoxycholic acid modulates lipid homeostasis gene expression in the liver.

(A) Hepatic mRNA levels of genes involved in lipogenesis and lipid uptake were measured by quantitative real-time PCR. All mRNA levels were normalized to large ribosomal protein *Rplp0* expression. n=3 mice/group for males, and 6 mice/group for females. Results are expressed as the mean±SEM. **Statistical testing was performed by two-way analysis of variance using gender and drug as factors. No significant differences among groups were observed for Srebp-1c. For the remaining genes, a significant interaction was observed between gender and drug, demonstrating that the difference of gender results in altered response to UDCA. Bars with different letters are significantly different, $p < 0.05$.** (B) Protein levels of hepatic peroxisome proliferator-activated receptor gamma (PPARG) were measured by western blotting.

Figure 4. Ursodeoxycholic acid downregulates inflammatory gene expression in liver and adipose tissues.

mRNA levels of inflammatory genes from (A) liver and (B) white adipose tissues were measured by quantitative real-time PCR. All mRNA levels were normalized to large ribosomal protein *Rplp0* expression. n=3 mice/group for males, and 6 mice/group for females. Results are expressed as the mean±SEM. **Statistical testing was performed by two-way analysis of variance using gender and drug as factors. A statistical difference due to drug (but not gender) was evident for Ccl2 in liver. For the remaining genes, a significant interaction was observed between gender and drug, demonstrating that the difference of gender results in altered response to UDCA. Bars with different letters are significantly different, $p < 0.05$.**

REFERENCES

1. Arlia-Ciommo A, Piano A, Svistkova V, Mohtashami S and Titorenko VI (2014) Mechanisms underlying the anti-aging and anti-tumor effects of lithocholic bile acid. *Int J Mol Sci* 15, 16522-16543
2. Chiang JY (2009) Bile acids: regulation of synthesis. *J Lipid Res* 50, 1955-1966
3. Amador-Noguez D, Yagi K, Venable S and Darlington G (2004) Gene expression profile of long-lived Ames dwarf mice and Little mice. *Aging Cell* 3, 423-441
4. Amador-Noguez D, Dean A, Huang W, Setchell K, Moore D and Darlington G (2007) Alterations in xenobiotic metabolism in the long-lived Little mice. *Aging Cell* 6, 453-470
5. Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y and Darnis F (1987) Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? *Lancet* 1, 834-836
6. Lazaridis KN, Gores GJ and Lindor KD (2001) Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. *J Hepatol* 35, 134-146
7. Zollner G, Fickert P, Fuchsbichler A et al. (2003) Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. *J Hepatol* 39, 480-488
8. Trauner M, Meier PJ and Boyer JL (1998) Molecular pathogenesis of cholestasis. *N Engl J Med* 339, 1217-1227
9. Bellentani S (2005) Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? *Eur J Gastroenterol Hepatol* 17, 137-140
10. Rodrigues CM, Fan G, Wong PY, Kren BT and Steer CJ (1998) Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. *Mol Med* 4, 165-178

11. Lukivskaya O, Patsenker E and Buko VU (2007) Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress. *Life Sci* 80, 2397-2402
12. Quintero P, Pizarro M, Solis N et al. (2014) Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. *J Physiol Biochem* 70, 667-674
13. Nie B, Park HM, Kazantzis M et al. (2012) Specific bile acids inhibit hepatic fatty acid uptake in mice. *Hepatology* 56, 1300-1310
14. Castro RE, Ferreira DM, Afonso MB et al. (2013) miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. *J Hepatol* 58, 119-125
15. Postic C and Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. *J Clin Invest* 118, 829-838
16. Pathil A, Mueller J, Warth A, Chamulitrat W and Stremmel W (2012) Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. *Hepatology* 55, 1369-1378
17. Ye R and Scherer PE (2013) Adiponectin, driver or passenger on the road to insulin sensitivity? *Mol Metab* 2, 133-141
18. van de Meeberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CM and Vanberge-Henegouwen GP (1997) Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. *Scand J Gastroenterol* 32, 369-373

19. Roda E, Azzaroli F, Nigro G et al. (2002) Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. *Dig Liver Dis* 34, 523-527
20. Tsuchida T, Shiraishi M, Ohta T, Sakai K and Ishii S (2012) Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. *Metabolism* 61, 944-953
21. Lee JM, Gang GT, Kim DK et al. (2014) Ursodeoxycholic acid inhibits liver X receptor alpha-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE. *J Biol Chem* 289, 1079-1091
22. Mueller M, Thorell A, Claudel T et al. (2015) Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. *J Hepatol* 62, 1398-1404
23. Link JC, Chen X, Prien C et al. (2015) Increased High-Density Lipoprotein Cholesterol Levels in Mice With XX Versus XY Sex Chromosomes. *Arterioscler Thromb Vasc Biol* 35, 1778-1786
24. Voshol PJ, Haemmerle G, Ouwens DM et al. (2003) Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice. *Endocrinology* 144, 3456-3462
25. Nunes PM, Jones JG, Rolo AP, Palmeira CM and Carvalho RA (2011) Ursodeoxycholic acid treatment of hepatic steatosis: a (^{13}C) NMR metabolic study. *NMR Biomed* 24, 1145-1158
26. Chung HY, Cesari M, Anton S et al. (2009) Molecular inflammation: underpinnings of aging and age-related diseases. *Ageing Res Rev* 8, 18-30
27. Shoelson SE, Lee J and Goldfine AB (2006) Inflammation and insulin resistance. *J Clin Invest* 116, 1793-1801






Fig. 1






Oh AR & Bae JS et al., BMB Reports, Figure 3

Fig. 3

A Liver



B Adipose tissue




Fig. 4

Supplementary Table S1. Primer sequences for quantitative real-time PCR

Gene symbol	Forward primers (5' to 3')	Reverse primers (5' to 3')
<i>Acaca</i>	GGCAGCTCTGGAGGTGTATG	TCCTTAAGCTGGCGGTGTT
<i>Adipoq</i>	TCACGGTGTACATGAAAGATGTG	GAGAACGGCCTTGTCTTCT
<i>Ccl2</i>	TCTGGGCCTGCTGTTTACA	CCAGCCTACTCATTGGGATCA
<i>Cd36</i>	GGAAGTGTGGGCTCATTGC	CATGAGAATGCCTCCAAACAC
<i>Cd163</i>	CGCCCCGCTAGACAGA	CGAATATCTATGTATCGTGAGCAGACT
<i>Chrebp-a</i>	CGACTCACCCACCTCTTC	TTGTTTCAGCCGGATCTTGTC
<i>Chrebp-b</i>	CAGATCGCGTGGAGCTCAGT	GGCATAGCAACTTGAGGCCTTT
<i>Fasn</i>	GCTGCGGAAACTTCAGGAAAT	AGAGACGTGTCACTCCTGGACTT
<i>Il1b</i>	TGACGGACCCCAAAGATG	TGGACAGCCAGGTCAAAG
<i>Il6</i>	CTGCAAGAGACTTCCATCCAGTT	AAGTAGGGAAGGCCGTGGTT
<i>Ldlr</i>	AGGCTGTGGCTCCATAGG	TGCGGTCCAGGGTTCATCT
<i>Lep</i>	TCAAGACCATTGTCACCAGGA	GTGAAGCCCAGGAATGAAGTC
<i>Me1</i>	ATCACTTTGGATGTGGGAACAG	CAGGAAGGCGTCATACTCAGG
<i>Mttp</i>	AGCCAGTGGGCATAGAAAATC	GGTCACTTTACAATCCCCAGA
<i>Pparg</i>	CAAGAATACCAAAGTGCGATCAA	GAGCTGGGTCTTTTCAGAATAATAAG
<i>Rplp0</i>	CACTGGTCTAGGACCCGAGAAG	GGTGCCTCTGGAGATTTTCG
<i>Scd1</i>	CCGGAGACCCCTTAGATCGA	TAGCCTGTAAAAGATTTCTGCAAACC
<i>Srebp-1c</i>	GGAGCCATGGATTGCACATT	GGCCCGGAAGTCACTGT
<i>Tnfa</i>	CTGAGGTCAATCTGCCCAAGTAC	CTTCACAGAGCAATGACTCCAAAG